Sofwave Medical Reports First Half Financial Results and Business Highlights
- Revenue Grew 34% YoY to $13.7M in the First Half - Pulse Recurring Revenue Increased to $2.9M - Announced...
Clinical Trial
Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNI® Surgical System in Patients with Open Angle Glaucoma
Three-year, standalone (not combined with cataract surgery) data shows the non-implantable minimally invasive glaucoma surgery effectively reduces intraocular pressure and...
Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-1660 in Breast, Endometrial and Ovarian Cancers
CAMBRIDGE, Mass., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering...
Opthea Announces Presentation at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
MELBOURNE, Australia, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies...
Lumos Pharma Announces Share Repurchase Program
-- Plan to Repurchase Up to $3 Million of Common Shares -- AUSTIN, Texas, Aug. 16, 2022 (GLOBE NEWSWIRE) --...
Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Q2 2022 FastPack ® Sales increased approximately 28%, and gross profit on product sales was up 64% year-over-year from Q2...
Bio-Path Holdings Reports Second Quarter 2022 Financial Results
Conference Call to be Held Today at 8:30 A.M. ETHOUSTON, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH),...
MediciNova Reaches Agreement to Participate in Grant-Funded Clinical Trial to Evaluate MN-166 (ibudilast) for the Treatment of Long COVID
LA JOLLA, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market...
ContraFect Announces Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis
YONKERS, N.Y., Aug. 15, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery...
Plus Therapeutics Presents Positive Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases
AUSTIN, Texas, Aug. 13, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative,...
Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders
Meeting adjourned only with respect to reverse stock split proposal until September 8, 2022SAN DIEGO, Aug. 12, 2022 (GLOBE NEWSWIRE)...
Biofrontera Inc. Reports Second Quarter 2022 Financial Results and Provides a Business Update
Conference call begins at 11:00 a.m. Eastern time today WOBURN, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq:...
POINT Biopharma Reports Second Quarter 2022 Financial Results and Provides Business Highlights
Additional data from the lead-in of PNT2002's SPLASH trial on track for fall 2022 release PNT6555, the lead of the...
Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
Positive interim results from registration-enabling study of cosibelimab in locally advanced cutaneous squamous cell carcinoma announced in June 2022 Successful...
VYNE Therapeutics Reports Second Quarter 2022 Financial Results
BRIDGEWATER, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company...
Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Paltusotine’s Phase 3 PATHFNDR Program in Acromegaly and Phase 2 Program in Carcinoid Syndrome Remain on Track for Top-Line Data...
PepGen Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
BOSTON, Aug. 12, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide...
Terns Announces $65 Million Oversubscribed Offering
FOSTER CITY, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage...
H1 Launches AI-Powered and Evidence-Based Interactions to Meet the Evolving Needs of Pharmaceutical and Biotech Medical Affairs Teams
New capabilities within H1’s HCP Universe platform empower corporate Medical Affairs and MSL teams to act faster and more effectively...
Panbela Announces First Patient Enrolled in its Aspire Trial Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Expects interim data by early 2024MINNEAPOLIS, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage...